© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
9500 EUCLID AVE
June 14, 2019
Research evaluated whether initiating breast cancer screening at age 30 may be preferable to current guidelines among survivors of childhood cancer with a history of chest irradiation.
June 13, 2019
The results of the first randomized clinical trial evaluating the link between a low-fat diet and breast cancer incidence and mortality were presented at ASCO 2019.
June 12, 2019
A subanalysis of the PROCEED trial showed a surprisingly high survival advantage for a particular race of men receiving immunotherapy for metastatic castration-resistant prostate cancer.
June 11, 2019
An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases.
June 10, 2019
Researchers tested simultaneous vs delayed rituximab with cladribine in patients with hairy cell leukemia.
The phase II IMmotion150 study evaluated disease- and treatment-related symptoms in RCC patients receiving atezolizumab alone or in combination with bevacizumab vs sunitinib.
Findings from a planned subanalysis of IMmotion151 looked at combination atezolizumab and bevacizumab in patients with RCC and sarcomatoid histology.
June 05, 2019
The study of sequential treatment of pazopanib followed by nivolumab in advanced or metastatic renal cell carcinoma looked at benefit-risk profile and survival.
The RELAY trial compared the combination of ramucirumab plus erlotinib vs erlotinib alone in patients with metastatic non–small-cell lung cancer.
A retrospective study finds that use of checkpoint inhibitors is associated with similar survival outcomes among patients with advanced non–small-cell lung cancer, regardless of a history of autoimmune disorders.